Emergent reduced its 2028 unsecured debt by $75 million at a discount while preserving liquidity and signaling active balance sheet management.
Rhea-AI Summary
Emergent BioSolutions (EBS) has completed the repurchase of $75 million aggregate principal of its 3.875% Senior Unsecured Notes due 2028, as authorized by its board.
The company spent approximately $68 million of cash, implying an average repurchase price of 90.6% of face value, and reduced the outstanding principal on these notes to about $364.7 million. Emergent states that the bond buyback aligns with its goal of strengthening its financial profile and managing its balance sheet during a multi‑year transformation. The company reports a strong cash position and access to an additional $50 million under its asset‑based revolving credit facility, and plans to monitor market conditions to evaluate timing for potential refinancing of the remaining notes. Management will discuss this milestone and its broader transformation progress at upcoming Wells Fargo and H.C. Wainwright healthcare investor conferences in September 2026.
Positive
- $75 million principal reduction of 3.875% Senior Unsecured Notes due 2028
- Repurchase completed at 90.6% of face value, implying a discount capture
- Cash outlay of approximately $68 million, less than principal retired
- Outstanding Senior Unsecured Notes lowered to about $364.7 million
- Additional liquidity from $50 million available under asset‑based revolver
Negative
- None.
Key Figures
Historical Context
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Historical reactions aligned with the apparent event direction in 4 of 5 selected events, while one informational announcement diverged.
Key Terms
senior unsecured notes financial
aggregate principal amount financial
asset-based revolving loan facility financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Repurchase reduces unsecured note balance to approximately $364.7 million
- Management to discuss this key milestone and broader transformation progress at upcoming investor conferences
GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has completed the repurchase of
“This bond repurchase reflects our continued discipline in deploying capital to strengthen Emergent’s financial profile while maintaining flexibility to support our strategic growth priorities,” said Joe Papa, president and CEO of Emergent. “The transactions were executed at attractive market levels, reduced our outstanding unsecured debt and further demonstrate our commitment to prudent balance sheet management as we continue advancing our multi-year transformation plan.”
Emergent continues to maintain a strong cash position on its balance sheet and has access to an additional
Emergent management will discuss this important milestone, along with the company’s broader transformation progress, at the following investor conferences:
- 21st Annual Wells Fargo Healthcare Conference, September 9, 2026
- H.C. Wainwright 28th Annual Global Investment Conference, September 14, 2026
- Presentation and webcast to be held at 3:30 pm ET; register here. A replay will be made available on Emergent’s Investor page.
- Presentation and webcast to be held at 3:30 pm ET; register here. A replay will be made available on Emergent’s Investor page.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding our ability to opportunistically deploy capital, the potential refinancing of additional Senior Unsecured Notes and our multi-year transformation plan, are forward-looking statements. We generally identify forward-looking statements by using words like "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "future," "goal," "intend," "may," "plan," "position," "possible," "potential," "predict," "project," "should," "target," "will," "would," and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements.
These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statement will be accurate. Readers should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement, as contained herein. Any such forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake any obligation to update any forward-looking statement to reflect new information, events or circumstances.
There are a number of important factors that could cause the company's actual results to differ materially from those indicated by any forward-looking statements. Readers should consider this cautionary statement, as well as the risks identified in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
[email protected]
Media Contact:
Assal Hellmer
Vice President, Communications
[email protected]
